Swissmedic

Type: Organization
Name: Swissmedic
First reported Jul 16 2014 - Updated Jul 17 2014 - 1 reports

ECCRT, a SynteractHCR Company, Continues to Garner Recognition and Partners for Clinical Trials Training Courses

European Centre for Clinical Research Training recognized by SwissEthics Committees and partners with ACRP due to its high trainingstandardsRelated Biotechnology, Pharmaceutical and Healthcare NewsThe European Centre for Clinical Research Training ( ECCRT ... [Published BioPortfolio - Jul 16 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Sucampo wins Swissmedic's approval for opioid-induced constipation treatment

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, has won an approval from Swissmedic, the Swiss Agency for Therapeutic Products, for AMITIZA 24mcg for the treatment of opioid-induced constipation, or OIC, in adults with chronic, non-cancer ... [Published Individual.com - Jul 16 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Measures for improved patient safety in cardiac surgery

The Federal Office of Public Health (FOPH) was informed that rare cases of infection with the bacterium Mycobacterium chimaera were detected after cardiac surgery involving implants. This bacterium occurs naturally in the environment (for example in drinking ... [Published Noodls - Jul 14 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

VERTEX PHARMACEUTICALS : Receives European CHMP Positive Opinion for KALYDECO™ ivacaftor in Eight Non-G551D Gating Mutations

By a News Reporter-Staff News Editor at Pharma Business Week -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval ... [Published 4 Traders - Jul 10 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 3 reports

Swissmedic approves Amitiza for opioidinduced constipation

US biopharma firm Sucampo Pharmaceuticals has received approval from Swissmedic, Switzerland’s Agency for Therapeutic Products, for Amitiza (lubiprostone) 24mcg for the treatment of opioid-induced constipation in adults with chronic, non-cancer pai.. ... [Published BioPortfolio - Jul 08 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

CHMP recommends approval of Vertex's Kalydeco for people with cystic fibrosis

The European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Vertex Pharmaceuticals' Kalydeco (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D ... [Published PharmaBiz - Jul 01 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 2 reports

Vertex Pharmaceuticals : Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations

-In Europe, approximately 250 people ages 6 and older have one of 8additional gating mutations--KALYDECO is the first medicine to treat the underlying cause of CFin people with non-G551D gating mutations-VertexPharmaceuticals Incorporated (Nasdaq: VRTX) ... [Published 4 Traders - Jun 27 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Cargologic - Consensus and efficiency

After 30 years in forwarding, logistics and airfreight, ten of which were with Cargologic, Marco Gredig became the firm’s CEO on 1 January 2014. He succeeded Peter Somaglia, who remains president of the Air Cargo Switzerland interest group. As Gredig ... [Published Transport Journal - Jun 20 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Newron, Zambon seek marketing nod for Parkinson’s disease drug, safinamide from Swissmedic

Newron Pharmaceuticals, a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, announced that the ... [Published PharmaBiz - Apr 09 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

Swissmedic approves ThromboGenics' Jetrea for vitreomacular traction treatment

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announced that Swissmedic has approved Jetrea (ocriplasmin) for the treatment of adults with vitreomacular traction (VMT), ... [Published PharmaBiz - Mar 20 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Swiss Agency approves ThromboGenics' Jetrea to treat vitreomacular traction

Swissmedic, the Swiss Agency for Therapeutic Products, has approved ThromboGenics' Jetrea (ocriplasmin) for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 m ... [Published Pharmaceutical Business Review - Mar 19 2014]

Quotes

...year in Switzerland, and its debilitating effects can lead to these patients discontinuing opioid therapy," said Peter Greenleaf, CEO of Sucampo. "We are pleased by Swissmedic's decision and look forward to providing physicians with an important new option to help treat the unmet needs of their patients."
...cause of the disease for people with these mutations," said Jeffrey Chodakewitz , M D , Senior Vice President and Chief Medical Officer at Vertex. "Today's recommendation for the use of ivacaftor in people with eight additional gating mutations represents an important step toward our goal of helping more people with CF."
Dr Patrik De Haes, CEO of ThromboGenics, says: "The approval of Jetrea by Swissmedic is another important milestone in the ensuring that Jetrea is available to as many patients as possible. This latest approval confirms our strong belief that Jetrea, in time, will become the treatment of choice for the earlier treatment of patients with VMT."
...Justin Gover said the approval in Switzerland marks yet another regulatory success for Sativex, which is now approved in a total of 23 countries. "We now look forward to working with our partners, Almirall, towards this launch so as to enable MS patients in Switzerland to benefit from this important new treatment" Gover said. Sativex is currently approved for use in the treatment of MS spasticity in 23 countries, including 17 countries in Europe

More Content

All (17) | News (16) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
ECCRT, a SynteractHCR Company, Continues to Gar... [Published BioPortfolio - Jul 16 2014]
Sucampo wins Swissmedic's approval for opioid-i... [Published Individual.com - Jul 16 2014]
Measures for improved patient safety in cardiac... [Published Noodls - Jul 14 2014]
VERTEX PHARMACEUTICALS : Receives European CHMP... [Published 4 Traders - Jul 10 2014]
Swissmedic approves Amitiza for opioidinduced c... [Published BioPortfolio - Jul 08 2014]
Swissmedic approves Amitiza for opioid-induced ... [Published Pharma Letter - Jul 08 2014]
Sucampo Pharmaceuticals, Inc. Release: Approves... [Published BioSpace - Jul 08 2014]
Swissmedic Approves AMITIZA(R) (Lubiprostone) f... [Published GlobeNewswire: Acquisitions News - Jul 07 2014]
CHMP recommends approval of Vertex's Kalydeco f... [Published PharmaBiz - Jul 01 2014]
Vertex Pharmaceuticals : Receives European CHMP... [Published 4 Traders - Jun 27 2014]
Vertex Receives European CHMP Positive Opinion ... [Published BusinessWeek - Jun 27 2014]
Cargologic - Consensus and efficiency [Published Transport Journal - Jun 20 2014]
Newron, Zambon seek marketing nod for Parkinson... [Published PharmaBiz - Apr 09 2014]
Swissmedic approves ThromboGenics' Jetrea for v... [Published PharmaBiz - Mar 20 2014]
Swiss Agency approves ThromboGenics' Jetrea to ... [Published Pharmaceutical Business Review - Mar 19 2014]
GW Pharmaceuticals' multiple sclerosis drug Sat... [Published Pharmaceutical Business Review - Nov 28 2013]
GW Pharma's Sativex receives Swiss approval [Published PharmaBiz - Nov 28 2013]
1
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
Swissmedic Approves AMITIZA(R) (Lubiprostone) f... [Published GlobeNewswire: Acquisitions News - Jul 07 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.